CLINICAL TRIAL: ADULT PATIENTS W/RELAPSED OR REFRACTORY B-LINEAGE ACUTE LYMPHOBL

这个子项目是许多利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 一项人IgM单克隆抗体（MAb 216）的I期试验，该抗体可杀死B谱系细胞，包括急性B淋巴母细胞性白血病，有或无补体。 试验将在复发性或难治性B系ALL成人患者中研究抗体单药给药和与长春新碱联合给药的安全性、药代动力学和抗肿瘤活性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A Phase I trial of a human IgM monoclonal antibody (MAb216) that kills B lineage cells including acute B lymphoblastic leukemia, with or without complement. Trial will study safety, pharmacokinetics and anti-tumor acitivity of the antibody given as a single agent and with vincristine in adult patients with relapsed or refractory B lineage ALL.